Technical Analysis for ERYP - Erytech Pharma S.A.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
7.165 | -1.81% | -0.13 |
ERYP closed down 1.81 percent on Friday, January 17, 2020, on 1.66 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Flat |
| Historical ERYP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Shooting Star Candlestick | Bearish | 0.00% | |
| Lizard Bearish | Bearish Day Trade Setup | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Narrow Range Bar | Range Contraction | -1.81% | |
| NR7 | Range Contraction | -1.81% | |
| NR7-2 | Range Contraction | -1.81% | |
| Wide Bands | Range Expansion | -1.81% | |
| Gapped Up | Strength | -1.81% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2019
- Sector: Healthcare
- Industry: Biotechnology
Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The Company's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death. The Company's subsidiary is Erytech Pharma, Inc in the USA which legal existence began in April 9, 2014.
Medicine Biopharmaceutical Cancer Clinical Medicine Antineoplastic Drugs Leukemia Acute Lymphoblastic Leukemia Asparaginase Medicinal Products
Medicine Biopharmaceutical Cancer Clinical Medicine Antineoplastic Drugs Leukemia Acute Lymphoblastic Leukemia Asparaginase Medicinal Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.89 |
| 52 Week Low | 3.9458 |
| Average Volume | 4,209 |
| 200-Day Moving Average | 6.94 |
| 50-Day Moving Average | 5.41 |
| 20-Day Moving Average | 6.44 |
| 10-Day Moving Average | 7.17 |
| Average True Range | 0.45 |
| ADX | 38.47 |
| +DI | 47.73 |
| -DI | 13.38 |
| Chandelier Exit (Long, 3 ATRs ) | 6.72 |
| Chandelier Exit (Short, 3 ATRs ) | 5.85 |
| Upper Bollinger Band | 8.71 |
| Lower Bollinger Band | 4.16 |
| Percent B (%b) | 0.66 |
| BandWidth | 70.67 |
| MACD Line | 0.57 |
| MACD Signal Line | 0.56 |
| MACD Histogram | 0.0115 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.54 | ||||
| Resistance 3 (R3) | 8.69 | 8.39 | 8.31 | ||
| Resistance 2 (R2) | 8.39 | 8.04 | 8.31 | 8.23 | |
| Resistance 1 (R1) | 7.78 | 7.82 | 7.62 | 7.62 | 8.16 |
| Pivot Point | 7.47 | 7.47 | 7.39 | 7.39 | 7.47 |
| Support 1 (S1) | 6.86 | 7.12 | 6.71 | 6.71 | 6.17 |
| Support 2 (S2) | 6.56 | 6.90 | 6.48 | 6.10 | |
| Support 3 (S3) | 5.95 | 6.56 | 6.02 | ||
| Support 4 (S4) | 5.79 |
